Vogenx, Inc. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2026-10: Study NCT07760961; Company role Lead sponsor; Phase Phase 2; Status Not yet recruiting.
- 2023-06-23: Study NCT05721729; Company role Lead sponsor; Phase Phase 2; Status Completed.
- 2022-09-13: Study NCT05541939; Company role Lead sponsor; Phase Phase 2; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2026-10 | NCT07760961 Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia | Lead sponsor | Phase 2 | Not yet recruiting | Postbariatric Hypoglycemia | 36 | 2028-01 |
| 2023-06-23 | NCT05721729 Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions | Lead sponsor | Phase 2 | Completed | Postbariatric Hypoglycemia | 15 | 2025-06-01 |
| 2022-09-13 | NCT05541939 Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects | Lead sponsor | Phase 2 | Completed Results posted | Postbariatric Hypoglycemia | 9 | 2023-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |